JP2016526576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526576A5 JP2016526576A5 JP2016527011A JP2016527011A JP2016526576A5 JP 2016526576 A5 JP2016526576 A5 JP 2016526576A5 JP 2016527011 A JP2016527011 A JP 2016527011A JP 2016527011 A JP2016527011 A JP 2016527011A JP 2016526576 A5 JP2016526576 A5 JP 2016526576A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- indol
- methoxy
- piperidin
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846355P | 2013-07-15 | 2013-07-15 | |
| US61/846,355 | 2013-07-15 | ||
| US201461977028P | 2014-04-08 | 2014-04-08 | |
| US61/977,028 | 2014-04-08 | ||
| PCT/US2014/046515 WO2015009616A1 (en) | 2013-07-15 | 2014-07-14 | Piperidinyl indole derivatives and their use as complement factor b inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526576A JP2016526576A (ja) | 2016-09-05 |
| JP2016526576A5 true JP2016526576A5 (enExample) | 2018-05-31 |
| JP6378761B2 JP6378761B2 (ja) | 2018-08-22 |
Family
ID=51230246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527011A Active JP6378761B2 (ja) | 2013-07-15 | 2014-07-14 | ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用 |
Country Status (40)
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109641838A (zh) * | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| MX2018016046A (es) | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| CN113444094B (zh) * | 2016-07-20 | 2023-12-22 | 纳莹(上海)生物科技有限公司 | 一种荧光探针及其制备方法和用途 |
| FI3985002T3 (fi) | 2017-03-01 | 2025-07-30 | Achillion Pharmaceuticals Inc | Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| JP6754919B1 (ja) | 2017-08-31 | 2020-09-16 | ノバルティス アーゲー | ピペリジニルインドール誘導体の新規な使用 |
| KR20210032950A (ko) * | 2018-07-16 | 2021-03-25 | 노파르티스 아게 | 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법 |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| CN112839945A (zh) | 2018-09-06 | 2021-05-25 | 艾其林医药公司 | 补体因子d抑制剂的形态形式 |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| US20220117949A1 (en) | 2019-01-11 | 2022-04-21 | Novartis Ag | Lta4h inhibitors for the treatment of hidradenitis suppurativa |
| US12435150B2 (en) | 2019-01-11 | 2025-10-07 | Novartis Ag | Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa |
| EP4106727A1 (en) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Pharmaceutical formulations |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| CN115667240B (zh) * | 2020-05-18 | 2025-04-22 | 诺华股份有限公司 | Lnp023的结晶形式 |
| US11951101B2 (en) | 2020-07-16 | 2024-04-09 | Novartis Ag | Methods of using factor B inhibitors |
| WO2022013604A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Methods of using factor b inhibitors |
| CN114057692B (zh) * | 2020-08-07 | 2023-07-21 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
| CN119219649A (zh) * | 2020-08-07 | 2024-12-31 | 武汉朗来科技发展有限公司 | 补体因子b抑制剂及其药物组合物、制备方法和用途 |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2022143845A1 (zh) | 2020-12-30 | 2022-07-07 | 江苏恒瑞医药股份有限公司 | 含氮桥杂环化合物、其制备方法及其在医药上的应用 |
| CA3203447A1 (en) * | 2020-12-30 | 2022-07-07 | Kevin X Chen | Series of piperidine-substituted benzoic acid compounds, and use thereof |
| CN116848238A (zh) * | 2021-01-14 | 2023-10-03 | 阿雷克森制药公司 | 大环补体因子b抑制剂 |
| EP4324828A4 (en) * | 2021-04-16 | 2025-06-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS |
| AU2022269405A1 (en) * | 2021-05-07 | 2023-11-16 | Novartis Ag | Iptacopan for the treatment of atypical hemolytic uremic syndrome |
| MX2023014274A (es) * | 2021-06-03 | 2024-04-22 | Chinook Therapeutics Inc | Compuestos indol sustituidos y metodos de uso de los mismos. |
| EP4355329A1 (en) | 2021-06-18 | 2024-04-24 | Novartis AG | Method of treating an autoimmune hematological disorder |
| EP4362933A4 (en) * | 2021-06-30 | 2025-06-04 | Apellis Pharmaceuticals, Inc. | COMPLEMENT INHIBITION |
| JP2024532847A (ja) | 2021-08-18 | 2024-09-10 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | ベンズアゼピン芳香環誘導体及びその医薬的な応用 |
| EP4398906A1 (en) | 2021-09-07 | 2024-07-17 | Novartis AG | Use of factor b inhibitors for the treatment of age-related macular degeneration |
| WO2023072197A1 (en) * | 2021-10-27 | 2023-05-04 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
| CA3247772A1 (en) | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses |
| WO2023143293A1 (zh) | 2022-01-26 | 2023-08-03 | 上海美悦生物科技发展有限公司 | 补体因子b抑制剂的盐型、晶型及其制备方法和应用 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| AU2023229221A1 (en) | 2022-03-04 | 2024-08-15 | Novartis Ag | Use of iptacopan for the treatment of lupus nephritis |
| EP4504699A1 (en) | 2022-04-01 | 2025-02-12 | Novartis AG | Complement factor b inhibitors and uses thereof |
| CN119698414A (zh) * | 2022-06-20 | 2025-03-25 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
| CN119546585A (zh) * | 2022-06-23 | 2025-02-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
| JP2025521830A (ja) * | 2022-06-30 | 2025-07-10 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法 |
| TWI879050B (zh) * | 2022-08-29 | 2025-04-01 | 新加坡商康哲研發有限公司 | 一系列含氮橋雜環化合物及其製備方法 |
| WO2024049977A1 (en) * | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
| AU2023339335A1 (en) | 2022-09-10 | 2025-04-03 | Hansoh Bio Llc | 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof |
| WO2024099458A1 (zh) * | 2022-11-11 | 2024-05-16 | 上海医药工业研究院有限公司 | 哌啶取代的苯甲酸类化合物、其药物组合物和应用 |
| WO2024104292A1 (en) * | 2022-11-14 | 2024-05-23 | Novartis Pharma Ag | Solid forms of complement factor b inhibitors |
| CN120303261A (zh) * | 2022-11-29 | 2025-07-11 | 上海济煜医药科技有限公司 | 苯并螺环吲哚化合物的制备、应用及用途 |
| CN120435467A (zh) * | 2022-12-31 | 2025-08-05 | 珠海联邦制药股份有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
| WO2024148274A1 (en) * | 2023-01-05 | 2024-07-11 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| WO2024175028A1 (zh) | 2023-02-22 | 2024-08-29 | 西藏海思科制药有限公司 | 一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用 |
| WO2024176169A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Methods of using factor b inhibitors |
| TW202438499A (zh) * | 2023-03-21 | 2024-10-01 | 大陸商上海美悦生物科技發展有限公司 | 螺環類化合物及其藥物組合物、製備方法和用途 |
| AU2024261191A1 (en) | 2023-04-27 | 2025-11-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt of piperidylindole compound and preparation method therefor |
| WO2025008453A1 (en) | 2023-07-04 | 2025-01-09 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors |
| WO2025008451A1 (en) | 2023-07-04 | 2025-01-09 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| TWI896250B (zh) * | 2023-07-26 | 2025-09-01 | 大陸商上海美悦生物科技發展有限公司 | 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途 |
| AU2024332373A1 (en) | 2023-08-25 | 2025-10-23 | Novartis Ag | Methods of using factor b inhibitors |
| TW202515541A (zh) | 2023-09-29 | 2025-04-16 | 瑞士商諾華公司 | 補體因子ｂ抑制劑及其用途 |
| WO2025083621A1 (en) | 2023-10-20 | 2025-04-24 | Novartis Ag | Treatment of hidradenitis suppurativa using anti-baff-r antibodies |
| TW202535375A (zh) * | 2023-12-05 | 2025-09-16 | 大陸商西藏海思科製藥有限公司 | 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途 |
| WO2025148628A1 (zh) * | 2024-01-10 | 2025-07-17 | 河北以岭医药研究院有限公司 | 哌啶基吲哚衍生物及其制备方法和应用 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| WO2025172910A1 (en) | 2024-02-16 | 2025-08-21 | Novartis Ag | Factor b inhibitors for treatment of anca-associated vasculitis |
| WO2025185734A1 (zh) * | 2024-03-08 | 2025-09-12 | 江苏豪森药业集团有限公司 | 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途 |
| WO2025237237A1 (en) * | 2024-05-11 | 2025-11-20 | Alebund Pharmaceuticals (Hong Kong) Limited | Complement factor b inhibitors |
| WO2025252133A1 (zh) * | 2024-06-07 | 2025-12-11 | 润尔眼科药物（广州）有限公司 | 一种含吲哚基团的化合物及其用途 |
| WO2025256647A1 (zh) * | 2024-06-14 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 化合物及其医药用途 |
| WO2026002007A1 (zh) * | 2024-06-25 | 2026-01-02 | 珠海联邦制药股份有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
| WO2026003809A1 (en) * | 2024-06-29 | 2026-01-02 | Assia Chemical Industries Ltd. | Solid state forms of iptacopan hydrochloride |
| WO2026008074A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的晶型、其制备方法及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR030357A1 (es) | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10217006A1 (de) | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| DE10237723A1 (de) | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
| SI1585743T1 (sl) | 2002-12-19 | 2007-08-31 | Pfizer | Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni |
| KR20060006954A (ko) | 2003-04-30 | 2006-01-20 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 단백질 티로신 포스파타제-１ｂ 억제제로서의 페닐 치환된카르복실산 |
| CA2587566A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| CA2594657A1 (en) * | 2005-02-08 | 2006-08-17 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| US20100197657A1 (en) | 2007-09-25 | 2010-08-05 | Chang Ronald K | 2-aryl or heteroaryl indole derivatives |
| WO2009076404A1 (en) | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| US8877944B2 (en) | 2009-07-14 | 2014-11-04 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors |
| RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN103402996B (zh) * | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| AP2014008040A0 (en) * | 2012-05-04 | 2014-10-31 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR20150033652A (ko) * | 2012-06-20 | 2015-04-01 | 노파르티스 아게 | 보체 경로 조절제 및 그의 용도 |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
-
2014
- 2014-07-13 JO JOP/2014/0224A patent/JO3425B1/ar active
- 2014-07-14 PL PL14744744T patent/PL3022192T3/pl unknown
- 2014-07-14 CN CN201480050471.1A patent/CN105579444B/zh active Active
- 2014-07-14 CA CA2917839A patent/CA2917839C/en active Active
- 2014-07-14 AP AP2016008992A patent/AP2016008992A0/xx unknown
- 2014-07-14 US US14/904,694 patent/US9682968B2/en active Active
- 2014-07-14 EA EA201690223A patent/EA031030B1/ru not_active IP Right Cessation
- 2014-07-14 WO PCT/US2014/046515 patent/WO2015009616A1/en not_active Ceased
- 2014-07-14 JP JP2016527011A patent/JP6378761B2/ja active Active
- 2014-07-14 EP EP14744744.5A patent/EP3022192B1/en active Active
- 2014-07-14 PT PT147447445T patent/PT3022192T/pt unknown
- 2014-07-14 RS RS20171318A patent/RS56721B1/sr unknown
- 2014-07-14 AU AU2014290298A patent/AU2014290298B2/en active Active
- 2014-07-14 ES ES14744744T patent/ES2655855T4/es active Active
- 2014-07-14 DK DK14744744.5T patent/DK3022192T3/en active
- 2014-07-14 BR BR112016000909-6A patent/BR112016000909B1/pt active IP Right Grant
- 2014-07-14 CU CU2016000006A patent/CU24397B1/es unknown
- 2014-07-14 TW TW103124190A patent/TWI641600B/zh active
- 2014-07-14 UA UAA201600266A patent/UA117371C2/uk unknown
- 2014-07-14 MX MX2016000662A patent/MX351291B/es active IP Right Grant
- 2014-07-14 PE PE2016000651A patent/PE20161066A1/es active IP Right Grant
- 2014-07-14 LT LTEP14744744.5T patent/LT3022192T/lt unknown
- 2014-07-14 TN TN2016000017A patent/TN2016000017A1/en unknown
- 2014-07-14 MY MYPI2020004691A patent/MY196427A/en unknown
- 2014-07-14 MY MYPI2016700023A patent/MY187454A/en unknown
- 2014-07-14 EP EP17191470.8A patent/EP3299365A1/en not_active Withdrawn
- 2014-07-14 SI SI201430522T patent/SI3022192T1/en unknown
- 2014-07-14 HU HUE14744744A patent/HUE037510T2/hu unknown
- 2014-07-14 HR HRP20172000TT patent/HRP20172000T1/hr unknown
- 2014-07-14 SG SG11201600086PA patent/SG11201600086PA/en unknown
- 2014-07-14 KR KR1020167003321A patent/KR102242742B1/ko active Active
- 2014-07-15 UY UY35663A patent/UY35663A/es active IP Right Grant
-
2016
- 2016-01-10 IL IL243540A patent/IL243540B/en active IP Right Grant
- 2016-01-11 PH PH12016500072A patent/PH12016500072A1/en unknown
- 2016-01-12 CL CL2016000060A patent/CL2016000060A1/es unknown
- 2016-01-14 SV SV2016005137A patent/SV2016005137A/es unknown
- 2016-01-14 GT GT201600007A patent/GT201600007A/es unknown
-
2017
- 2017-06-19 US US15/626,981 patent/US10093663B2/en active Active
-
2018
- 2018-01-08 CY CY20181100019T patent/CY1119767T1/el unknown
-
2019
- 2019-08-11 IL IL268623A patent/IL268623B/en active IP Right Grant
-
2024
- 2024-09-30 NO NO2024042C patent/NO2024042I1/no unknown
- 2024-10-01 HU HUS2400034C patent/HUS2400034I1/hu unknown
- 2024-10-01 FR FR24C1036C patent/FR24C1036I2/fr active Active
- 2024-10-01 LT LTPA2024526C patent/LTPA2024526I1/lt unknown
- 2024-10-01 FI FIC20240032C patent/FIC20240032I1/fi unknown
- 2024-10-02 CY CY2024027C patent/CY2024027I2/el unknown
- 2024-10-07 NL NL301292C patent/NL301292I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526576A5 (enExample) | ||
| HRP20172000T1 (hr) | Derivati piperidinil indola i njihova uporaba kao inhibitora komplementnog faktora b | |
| CN105764514B (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| JP2016516043A5 (enExample) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| JP2015515976A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2019536785A5 (enExample) | ||
| JP2018502877A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| JP2016512515A5 (enExample) | ||
| JP2014530900A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2017512786A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2016535042A5 (enExample) | ||
| HRP20161011T1 (hr) | Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2 | |
| JP2020516671A5 (enExample) | ||
| JP2005517006A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2016513681A5 (enExample) | ||
| JP2020502230A5 (enExample) |